US 12,466,803 B2
BCKDK inhibitors and/or degraders
Leanne Marie Buzon, Stonington, CT (US); Kimberly O'Keefe Cameron, Niantic, CT (US); Kevin Francis Deboyace, Mystic, CT (US); Kevin James Filipski, Reading, MA (US); David Andrew Griffith, Sudbury, MA (US); Bethany Lyn Kormos, Somerville, MA (US); Shenping Liu, Waterford, CT (US); Luis Angel Martinez Alsina, Gales Ferry, CT (US); Matthew Richard Reese, Mystic, CT (US); Rachel Jane Roth Flach, Rockland, MA (US); and Yuan Zhang, Mansfield, MA (US)
Assigned to Pfizer Inc., New York, NY (US)
Filed by Pfizer Inc., New York, NY (US)
Filed on Nov. 30, 2022, as Appl. No. 18/060,027.
Claims priority of provisional application 63/383,562, filed on Nov. 14, 2022.
Claims priority of provisional application 63/284,797, filed on Dec. 1, 2021.
Prior Publication US 2023/0167080 A1, Jun. 1, 2023
Int. Cl. C07D 333/68 (2006.01); A61P 3/04 (2006.01); A61P 9/00 (2006.01)
CPC C07D 333/68 (2013.01) [A61P 3/04 (2018.01); A61P 9/00 (2018.01); C07B 2200/13 (2013.01)] 16 Claims
 
16. A compound, wherein the compound is

OG Complex Work Unit Chemistry
or a mixture thereof.